GlassScriptPhysician profile
Muhammad O Jamil
NPI 1245545508
$437.66
in general payments reported to CMS, 2019-2025
12 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $77.04 · 2022: $47.23 · 2024: $51.93 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157 · Education: $51.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.95 |
| Education | $51.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.02 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.44 | 2019-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $52.32 | 2019-2024 | Welireg |
| Pfizer INC. | $47.00 | 2019-2020 | |
| Daiichi Sankyo INC. | $26.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.12 | 2020 | |
| Galvanize Therapeutics, INC | $22.08 | 2025 | Aliya System |
| Lilly USA, LLC | $21.59 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2022 | |
| Seagen INC. | $18.91 | 2019 | |
| Tempus Ai, INC | $15.85 | 2025 | Xt Cdx |
| Astellas Pharma US INC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.